Loading...

Home
ETF
RLMD

RLMD

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

RLMD News

BTIG Initiates Buy Rating on Invivyd Inc with $10 Price Target

Dec 22 2025Benzinga

Relmada Therapeutics Sets Price for $100 Million Underwritten Common Stock and Pre-Funded Warrant Offering

Nov 04 2025Newsfilter

Relmada Receives FDA Feedback Endorsing Two Distinct Acceptable Pathways for NDV-01 Registration Studies in Non-Muscle Invasive Bladder Cancer

Nov 04 2025Newsfilter

Relmada Therapeutics Welcomes Renowned Urologic Oncologist Max Kates, MD, to Clinical Advisory Board for NDV-01 Development

Oct 07 2025Newsfilter

Insider Buying Update for Tuesday, September 2: RLMD, STRA

Sep 02 2025NASDAQ.COM

Relmada outlines 2026 trial launches for NDV-01 and sepranolone as pipeline advances

Aug 08 2025SeekingAlpha

Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket

Jul 22 2025Benzinga

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 15 2025Newsfilter

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Jun 17 2025Newsfilter

Relmada Therapeutics Hires Raj S. Pruthi As Chief Medical Officer-Urology

Jun 17 2025NASDAQ.COM

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 08 2025Newsfilter

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 28 2025Newsfilter

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 27 2025Yahoo Finance

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 24 2025Newsfilter

Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

Apr 24 2025Benzinga

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 14 2025Newsfilter